Clinical Trial Update: PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain [Phase 4]

View source ↗

Summary

A Phase 4, non-interventional, open-label study evaluating TARGIN (oxycodone/naloxone) for cancer-related pain in Korean patients. Results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• TARGIN (oxycodone/naloxone)

Snippet

Sponsor: Mundipharma Korea Ltd | Conditions: Cancer | Phase 4 | Status: COMPLETED | Results posted: 2016-08-19